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Abstract:  Folic acid and methylenetetrahydrofolate reductase (MTHFR) may affect the 
development  of  human  cancer.  However,  few  studies  have  evaluated  folate  intake  and 
MTHFR in susceptibility to and prognosis of patients with ovarian cancer. We conducted a 
prospective case-control study in 215 ovarian cancer patients and 218 controls (all Chinese) 
between Jan. 2004 and Jan. 2007. MTHFR C677T genotyping was done by PCR-RFLP. All 
patients were followed up until Dec. 2010. We found a 2.43-fold increased risk of ovarian 
cancer  among  MTHFR  677TT  carriers,  and  a  decreased  risk  of  ovarian  cancer  in 
individuals  with  high  folate  intake  (OR  =  0.54,  95%  CI  =  0.32–0.94).  Cox  regression 
survival analysis showed that among the ovarian cancer patients, those carrying the 677TT 
genotype had a higher risk of death (HR = 2.17, 95% CI = 1.20–4.79), while high folate 
intake  was  associated  with  a  lower  risk  of  death  (HR  =  0.43,  95%  CI  =  0.33–0.88). 
Moreover, MTHFR 677CC carriers with higher folate intake showed a lower risk of death 
from ovarian cancer (HR = 0.32, 95% CI = 0.27–0.82). In summary, high folate intake may 
lessen  susceptibility  and  improve  the  prognosis  of  ovarian  cancer  patients,  while  the 
MTHFR 677TT genotype appears to increase ovarian cancer risk and worsen its prognosis 
in a Chinese population. 
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1. Introduction 
Ovarian  cancer  is  one  of  the  most  deadly  gynecological  cancers  worldwide  [1].  China  has  a 
relatively low ovarian cancer incidence of 3–5 per 10
5 females, which is about one-fourth the rate in 
northern Europe [2]. The wide geographic variation in incidence rates points to the role of genetic and 
environmental  factors  in  the  pathogenesis  of  this  cancer.  Possible  risk  factors  for  ovarian  cancer 
include family history, tobacco smoking, infertility, low parity, and hormone replacement therapy, 
while  oral  contraceptive  use  and  fewer  menstrual  cycles  are  associated  with  decreased  risk  [2,3]. 
Deficiency of nutrients, such as vitamins and microelements, has also been associated with increased 
risk for ovarian cancer, whereas high fruit and vegetable intake may help prevent the disease [4].  
Folate is a water-soluble vitamin naturally found in green leafy vegetables, cereals, legumes, and 
fruits.  It  plays  an  important  role  in  DNA  synthesis,  integrity,  and  stability,  and  folate  deficiency 
usually causes defective DNA repair and chromosomal fragile site expression, leading to chromosomal 
breaks and micronucleus formation. Moreover, folate plays a central role in DNA methylation [5–7]. 
Folate deficiency leads to ovarian cancer through two mechanisms: by inducing misincorporation of 
uracil into DNA, thus disrupting DNA integrity and DNA repair; and by altering DNA methylation, 
which can alter expression of critical tumor suppressor genes and proto-oncogenes [8–10].  
Methylenetetrahydrofolate reductase  (MTHFR) is  a central  enzyme in  folate metabolism  which 
catalyzes  the  reduction  of  5,10-methylene-tetrahydrofolate  to  5-methyltetrahydrofolate.  Methionine 
synthase  then  catalyzes  the  reaction  of  5-methyltetrahydrofolate  and  homocysteine  to  generate 
methionine  and  tetrahydrofolate.  Under  folate  deficiency  conditions,  MTHFR  may  cause  point 
mutations and/or chromosomal breaks, facilitate the conversion of 5,10-methylene THF to 5-methyl 
THF, and reduce the concentration of 5-methyl THF to decrease the conversion of homocysteine to 
methionine.  Ultimately,  MTHFR  plays  a  role  in  the  carcinogenesis  process  of  DNA  
hypomethylation  [11].  The  C677T  variant  (Ala222Val,  rs  1801133)  has  been  associated  with 
decreased  MTHFR  activity,  increased  homcysteine  levels,  and  an  altered  folate  distribution  [12]. 
Previous studies on the association between MTHFR C677T polymorphism and ovarian cancer have 
found conflicting results [4,13]. 
The roles of dietary folate and MTHFR C677T polymorphism in ovarian cancer are unclear and 
there have been few studies on this relationship in Chinese populations. However, low folate intake 
and inactive MTHFR C677T are associated with improved survival of cancer patients treated with 
first-line fluorouracil-based chemotherapy [14–16]. Since a folate pool imbalance and impaired repair 
mechanisms  may  result  in  DNA  instability  and  strand  breaks,  and  inactive  MTHFR  C677T  may 
accelerate the carcinogenesis process of DNA hypomethylation under folate deficiency conditions, we 
hypothesized that folate deficiency and inactive MTHFR C677T may influence both susceptibility to 
and progression of ovarian cancer. We tested this idea with a case-control study and a case-only cohort 
study in a Chinese population. Int. J. Mol. Sci. 2012, 13                  
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2. Results and Discussion 
2.1. Results 
We recruited 215 ovarian cancer patients diagnosed between Jan. 2004 and Jan. 2007 for this study. 
218 Controls were randomly selected from female people who requested general health examinations 
in the same hospital during the same period. Controls were required to be without any history of any 
type of cancer and frequency matched by five-year age groups. The average ages of cases and controls 
were  47.2  ±   7.5  years  and  47.6  ±   8.1  years,  respectively  (Table  1).  There  were  no  significant 
differences between cases and controls in age, drinking, tobacco use, menopausal status, or hormone 
replacement use. Ovarian cancer patients tended to have borne fewer children than had controls. Oral 
contraceptive  use  was  associated  with  a  lower  risk  of  ovarian  cancer,  while  ovarian  cancer  in  
first-degree relatives heightened cancer risk. Most of the cancer patients received chemotherapy; only 
6.0% of patients received radiotherapy. 
Table 1. Demographic and clinical characteristics of ovarian cancer patients. 
Variable  Cases, N (%)  Controls, N (%)  p value 
Age, years [mean, (sd)]  47.2, 7.5  47.6, 8.1  0.30 
Smoking status       
 Smokers  196 (91.2)  204 (93.5)  0.34 
 Nonsmokers  19 (8.8)  14 (6.5)   
Drinking status       
 Drinkers  169 (21.6)  177 (18.8)  0.50 
 Nondrinkers  46 (78.4)  41 (81.2)   
Number of deliveries       
0  27 (12.6)  12 (5.7)  <0.05 
1  85 (39.6)  79 (36.4)   
2  83 (38.7)  95 (43.7)   
≥3  20 (9.1)  31 (14.2)   
Menopausal status       
 Pre-menopausal  105 (48.7)  97 (44.3)  0.37 
 Post-menopausal  110 (51.3)  121 (55.7)   
Hormone replacement therapy       
 Never  203 (94.5)  212 (97.2)  0.14 
 Ever  12 (5.5)  6 (2.8)   
Oral contraceptive use       
Never  162 (75.3)  140 (64.4)  <0.05 
Ever  53 (24.7)  78 (35.6)   
Ovarian cancer in first-degree relatives       
 Yes  203 (94.4)  217 (99.994)  <0.05 
 No  12 (5.6)  1 (0.006)   
Tumor type       
Invasive  132 (61.6)     
Borderline  81 (37.5)     
Unknown  2 (0.9)     Int. J. Mol. Sci. 2012, 13                  
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Table 1. Cont. 
Variable  Cases, N (%)  Controls, N (%)  p value 
Chemotherapy       
 Yes  154 (71.6)     
 No  44 (20.5)     
Radiotherapy       
 Yes  13 (6.0)     
 No  185 (86.0)     
There was a significant difference in C677T polymorphisms between patients and controls (Table 2). 
Individuals with the TT genotype had an increased risk of developing ovarian cancer relative to those 
with the CC genotype (Adjusted OR = 2.43, 95% CI = 1.32–6.32). Individuals with high folate intake 
were less likely to develop ovarian cancer (OR = 0.54, 95% CI = 0.32–0.94). 
Table  2.  Frequency distribution and association of methylenetetrahydrofolate reductase 
(MTHFR) C677T genotypes and folate intake levels with ovarian cancer. 
Genotype/Allele  Cases, N (%)  Controls, N (%)  OR 
1 (95% CI)  OR 
2 (95% CI) 
MTHFR C677T         
CC  102 (47.3)  115 (52.8)  1.0 (Reference)  1.0 (Reference) 
CT  94 (43.9)  92 (42.1)  1.15 (0.76–1.74)  1.48 (0.94–2.15) 
TT  19 (8.8)  11 (5.1)  1.94 (0.83–4.75)  2.43 (1.32–6.32) 
T allele  113 (52.7)  103 (47.2)  1.24 (0.83–1.84)  1.67 (0.99–3.27) 
Daily folate consumption (µ g/day) 
Mean (SE)   257.4, 36.7  295.5, 28.6  -   
<200   61 (28.6)  46 (21.3)  1.0 (Reference)  1.0 (Reference) 
200–310  90 (41.7)  95 (43.7)  0.71 (0.43–1.19)  0.66 (0.41–1.05) 
>310  64 (29.7)  76 (35)  0.64 (0.37–1.09)  0.54 (0.32–0.94) 
1.  None  adjusted  OR.  2.  Adjusted  for  age,  tobacco  smoking,  alcohol  consumption,  number  of  deliveries, 
menopausal status, hormone replacement, oral contraceptive use, and ovarian cancer history. 
Patients were followed from diagnosis until the end of Dec. 2010. Seven of the 215 patients were 
lost to follow-up due to migration, while the remaining 208 patients completed the study. The median 
follow-up time was 48.2 months (range: 2–72 months). A total of 106 patients (50.9%) died of ovarian 
cancer during the follow-up period (Table 3). The 677TT genotype was associated with poor survival 
(HR = 2.17, 95% CI = 1.20–4.79) (Figure 1). We found an inverse relationship between folate intake 
and risk of death, with an average survival time of 40.5 months for individuals with low folate intake, 
and 56.2 months for those with the highest folate consumption (Figure 2). The HRs (95% CI) for moderate 
and high folate intake were 0.67 (0.40–1.03) and 0.43 (0.33–0.88), respectively (p for trend = 0.011).  Int. J. Mol. Sci. 2012, 13                  
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Table  3.  Kaplan-Meier  survival  estimation  of median  survival  and  HRs  with  MTHFR 
C677T gene polymorphism. 
  N (%)  Mean Survival, 95% 
CI (months) 
HR (95% CI), p value 
MTHFR C677T       
CC  98 (47.2)  54.5 (69.9–59.1)  1.0 (reference) 
CT  90 (43.1)  46.0 (40.1–51.9)  1.34 (0.89–2.18), 0.11 
TT  20 (9.7)  33.8 (24.6–43.0)  2.17 (1.20–4.79), <0.05 
Folate intake (µ g/day) 
<230  58 (27.9)  40.5 (34.5–46.5)  1.0 (reference) 
230–300  88 (42.2)  48.8 (42.9–54.7)  0.67 (0.40–1.03), 0.06 
>300  62 (29.9)  56.2 (50.2–62.3)  0.43 (0.33–0.88), <0.05 
Figure 1. Overall ovarian cancer survival by MTHFR gene polymorphism. 
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Figure 2. Overall ovarian cancer survival by folate intake level. 
 
We further explored the association between MTHFR C677T polymorphisms and ovarian cancer 
prognosis  according  to  folate  intake  level  (Table  4).  Among  individuals  with  a  folate  intake  
of 230–300 µg/day and >300 µg/day, MTHFR 677CC carriers showed a significantly lower risk of 
death risk from ovarian cancer, with adjusted HRs (95% CI) of 0.56 (0.39–0.96) and 0.32 (0.27–0.82), 
respectively. A significant interaction was found between folate consumption and MTHFR genotype  
(p = 0.024, data not shown). 
Table 4. MTHFR C677T polymorphisms and ovarian cancer prognosis according to folate 
intake level. 
Daily  folate 
consumption 
Genotype 
CC  Deaths 
N (%) 
HR  
(95% CI) 
1 
CT  Deaths 
N (%) 
HR  
(95% CI) 
1 
TT  Deaths 
N (%) 
HR  
(95% CI) 
1  Cases (%)  Cases  Cases 
<230 µ g/day 
30 (30.6) 
23 
(51.1) 
1.0 
(Reference) 
20 
(22.2) 
16 
(38.1) 
1.0 
(Reference) 
8 
(40.0) 
6 
(40.0) 
1.0 
(Reference) 
230–300 
µ g/day 
33 (33.7) 
14 
(31.1) 
0.56  
(0.39–0.96) 
48 
(53.3) 
18 
(42.9) 
0.59  
(0.42–1.27) 
7 
(35.0) 
5 
(33.3) 
1.25  
(0.84–1.45) 
>300 µ g/day 
35 (35.7) 
8 
(17.8) 
0.32  
(0.27–0.82) 
22 
(24.5) 
8 
(19.0) 
0.45  
(0.34–1.02) 
5 
(25.0) 
4 
(26.7) 
1.59  
(0.93–2.24) 
1  Adjusted  for  age,  tobacco  smoking,  alcohol  consumption,  number  of  deliveries,  menopausal  status, 
hormone replacement, oral contraceptive use, and ovarian cancer history. Int. J. Mol. Sci. 2012, 13                  
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2.2. Discussion 
Our  results  indicate  that  MTHFR  C677T  polymorphisms  are  associated  with  susceptibility  to 
ovarian  cancer,  and  high  folate  consumption  with  a  decreased  risk  of  ovarian  cancer.  Moreover, 
ovarian cancer patients with high folate consumption may have better survival than individuals with 
low diet folate intake. This protective effect was more evident in patients carrying MTHFR 677CC 
genotypes.  This  may  be  due  to  the  putative  effect  of  folate  metabolism  on  the  development  and 
prognosis of ovarian cancer. 
Folate mediates the transfer of one-carbon moieties both in the synthesis of nucleotides necessary 
for DNA synthesis, replication, and repair, and in DNA methylation reactions [17]. These functions 
may play a critical role in carcinogenesis. An abundant intake of folate-rich foodstuffs appears to 
convey protection against developing some cancers [18]. Our study provides further evidence of the 
protective  role  of  folate  intake.  Although  previous  epidemiological  studies  have  found  an  inverse 
association  between  folate  intake  and  cancer  risk  [19],  the  effect  of  folate  supplements  on 
carcinogenesis  remains  controversial  for  some  ethnic  groups  [6,20].  The  prevalence  of  variant 
genotypes of the MTHFR C677T polymorphism varies greatly among different human populations. In 
Africans, the frequency of MTHFR 677T/T is below 1%, whereas in Mexicans, it is above 30%. Its 
frequency  in  our  control  group  was  8.8%,  which  is  comparable  to  previous  reports  on  Chinese 
populations [21,22]. The different results found for the effect of folate intake on ovarian cancer risk in 
different ethnicities may be due to differences in population background, study design, sample size, 
environmental  factors,  and  chance  variations.  Further  confirmation  of  such  differential  effects  is 
therefore needed. 
We  found  a  significant  association  between  MTHFR  C677T  polymorphism  and  ovarian  cancer 
development and prognosis. However, previous studies have found inconsistent results for whether this 
association exists [13,23]. A study conducted in the United States and one Polish study both reported 
an association between these MTHFR SNPs and ovarian cancer development and prognosis [23,24], 
while another large sample study  from the United States did not find evidence for an association 
between MTHFR C677T and ovarian cancer risk [13]. Some biological data support a role for MTHFR 
C677T  polymorphism  in  cancer  survival.  Namely,  the  balance  of  the  5,10-MTHF  and  5-MTHF 
controlled by MTHFR may influence the efficacy of chemotherapy with 5-fluorouracil (5-FU). The 
inactive 677TT form could increase the amount of 5,10-MTHF. Cell line experiments suggest that 
fluoropyrimidines like 5-FU inhibit thymidylate synthetase by forming a ternary complex involving  
5-FU, thymidylate synthetase, and 5,10-MTHF [25]. Therefore, these MTHFR polymorphisms may 
enhance  the  effect  of  5-FU  by  increasing  the  amount  of  5,10-MTHF.  In  one  animal  study, 
administration of 5,10-MTHF enhanced the efficacy of 5-FU [26]. Another study showed that colon 
cancer  cases  with  inactive  MTHFR  677T/T  are  three  times  more  likely  to  respond  to  5-FU 
chemotherapy than are MTHFR 677C/C carriers [27]. In our study, most of the cases were treated with 
chemotherapy, and our results showed 677TT is associated with a higher risk of death from ovarian 
cancer, which indicates an interaction between MTHFR C677T polymorphism and chemotherapy. 
Our study showed high folate intake was associated with reduced risk of ovarian cancer among 
677C/C carriers, which indicates that folate and the active 677C/C genotype have a synergistic effect 
on ovarian cancer prognosis. This association between folate intake and reduced risk of death from Int. J. Mol. Sci. 2012, 13                  
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ovarian cancer was only found for the 677C/C genotype. Similarly, a study conducted in China on 
esophageal cancer also found a significant synergy between folate intake and the 677C/C genotype [28]. 
Our study has several limitations. First, we selected controls from hospital visitors, which may be a 
threat  to  the validity of the results.  This  method brings  a  certain  risk  of selection bias, since  the 
controls  were  not  a  random  sample  of  the  general  population  and  may  not  fully  represent  the 
underlying base population. However, all control subjects in our study were those who came to the 
hospital for routine health examinations, not hospitalized patients with specific diseases, so they were 
likely representative of the general population, and thus provide a reasonable estimate of the allele 
frequencies  of  MTHFR  C677T  variants.  Second,  the  small  number  of  patients  carrying  the 
homozygous mutation TT in this study  limited the statistical power of our analysis of differences 
among carriers of different genotypes. Increasing the number of controls to a control-case ratio of 2 or 
more can, at least to some extent, increase the study power. Therefore, further large-sample studies on 
this question are warranted. Third, collection of dietary habits information brings a risk of recall bias, 
which  may  have  exaggerated  or  reduced  the  effects  we  found.  We  suggest  that,  for  the  survival 
analysis, future studies could collect information on dietary habits during follow-up, which would 
greatly reduce recall bias. 
3. Experimental Section 
3.1. Study Subjects 
This was a case-control and case-only cohort study conducted in the Tianjin Medical University 
Cancer Institute and Hospital. All Chinese female cases newly diagnosed with primary ovarian cancer 
in the hospital between Jan. 2004 and Jan. 2007 were invited to face-to-face interviews within two 
months after diagnosis. All cases recruited in this study were histologically confirmed. A total of 215 
cases were selected and interviewed. Controls were randomly selected from people who requested 
general health examinations in the same hospital during the same period. Controls had no history of 
any type of cancer, and were frequency-matched by 5-year age groups. Among a total of 246 eligible 
controls, 218 were successfully interviewed and donated blood samples, with a participation rate of 
88.6%. All the patients were followed up until Dec. 2010, and we recorded all deaths of patients. 
3.2. Data Collection 
A face-to-face interview was conducted with a structured questionnaire to collect information on 
demographic factors and clinical  characteristics, menstrual  and reproductive history, hormone  use, 
dietary habits, tobacco and alcohol habits, and family history of ovarian cancer. The tobacco smoking 
status  were  divided  into  smokers  (smokers  were  defined  as  individuals  who  smoked  more  than  
20  packets  of  cigarettes  per  year,  or  smoked  more  than  one  cigarette  per  day  and  continued  for  
6 months) and nonsmokers, drinking status were divided into drinkers (defined as individuals who 
drank more than 100 g alcohol (400 mL beers, 250 wine mL and 100 mL white spirit) per month and 
continued for 6 months) and non-drinkers. Information on usual dietary intake was collected using a 
comprehensive quantitative food-frequency questionnaire (FFQ) with 95 items. The FFQ used in this 
study was based on a questionnaire designed by the US National Institutes of Health and modified Int. J. Mol. Sci. 2012, 13                  
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according to common Chinese food items and cooking habits. For each food item, we collected the 
frequency  and  quantity  of  consumption,  then  calculated  daily  intake  by  multiplying  the  reported 
consumption frequency for each food item by the portion size specified by the respondent. Soy food 
intake was estimated with 16 soy food items, including tofu, soy milk, soy yogurt, soy frozen yogurt, 
soy ice cream, soy cheese, soy hot dogs and cold cuts, other meat substitutes made from soy, tempeh, 
miso,  soybeans,  roasted soy nuts,  soy sauce, soybean sprouts,  alfalfa sprouts,  and protein powder 
supplements made from soy.  
The study protocol was approved by the Ethics Committee of the Affiliated Hospital of Sichuan 
University. Informed consent was obtained before each interview. 
3.3. Genotyping 
Genomic DNA was extracted from  whole-blood samples  using the Qiagen  Blood  Kit  (Qiagen, 
Chatsworth,  CA).  Genotyping  was  conducted  by  TaqMan  assays  using  the  ABI  Prism  7911HT 
Sequence  Detection  System  (Applied  Biosystems,  Foster  City,  CA).  Primer,  probes,  and  reaction 
conditions  were  based  on  those  of  our  previous  study [29].  Genotyping  was  done  by  laboratory 
personnel  blinded  to  case-control  status.  For  quality  control  purposes,  we  also  genotyped  internal 
positive  control  samples,  used  no-template  controls,  and  replicated  the  genotyping  of  10%  of  
the samples. 
3.4. Statistical Analysis 
All statistical analyses were performed using STATA 10.0 (College Station, TX, USA). Differences 
in demographic and clinic characteristics, as well as potential confounding factors, were tested using a 
chi-squared test. Previous studies showed that family history of ovarian cancer, reproductive factors, 
menopausal status and hormone replacement therapy were the risk factors for ovarian cancer [30], and 
these  factors  may  confound  the  association  between  MTHFR  C677T  polymorphism  and  ovarian 
cancer prognosis. Moreover, previous studies showed that there was interaction between MTHFR gene 
polymorphism and tobacco smoking and alcohol consumption [31–33]. Therefore, we adjusted the age, 
tobacco smoking, alcohol consumption, number of deliveries, menopausal status, hormone replacement, 
oral contraceptive use, and ovarian cancer history when analyzing the association between MTHFR 
C677T polymorphism and ovarian cancer prognosis. Unconditional logistic regression was undertaken 
to  estimate  odds  ratios  (ORs)  and  their  95%  confidence  intervals  (95%  CIs)  after  controlling  for 
potential confounding factors. In the logistic regression equation, the age was continuous variable, and 
tobacco smoking, alcohol consumption, number of deliveries, menopausal status, hormone replacement, 
oral contraceptive use, and ovarian cancer history were categorical variables. 
The outcome measured was overall survival, which was estimated using the Kaplan-Meir method. 
A univariate Cox regression analysis was used to assess the association between folate intake, MTHFR 
C677T-Arg399Gln  gene  polymorphisms,  and  survival.  A  primary  death  from  ovarian  cancer  was 
defined as a failure event, and the survival time was defined as the time between diagnosis and death. 
The cause of death was defined by specialists based on clinical documents and reports by patients’ 
family members. If a patient died from a cause other than ovarian cancer, her data was censored at the 
date of death. All surviving patients were censored at the date of last follow-up. Folate intake was Int. J. Mol. Sci. 2012, 13                  
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computed  by  multiplying  food  intake  (in  grams)  by  folate  content  (per  gram)  of  the  food,  then 
summing all folate intake from various foods to obtain the total folate intake. The continuous variable 
of folate intake was categorized as low, moderate, or high using tertiles as cut-off points. The relative 
risk [hazard ratio (HR)] and 95% CI were calculated with the Cox regression model for all significant 
predictors from cancer diagnosis to the endpoint of the study (event). All statistical tests were two 
sided, and differences were taken as significant when the P value was less than 0.05. 
4. Conclusions  
In this first study to investigate the association among folate intake, MTHFR C677T polymorphism, 
and ovarian cancer susceptibility and survival in a Chinese population, we found that high folate intake 
may  protect  against  the  development  and  improve  the  prognosis  of  ovarian  cancer.  The  677TT 
genotype appears to be positively associated with ovarian cancer risk and  poor disease prognosis. 
Further studies with larger sample sizes are needed in Chinese populations.  
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